Navigation Links
Galil Medical Announces the Appointment of Martin J. Emerson as President and Chief Executive Officer

YOKNEAM, Israel and PLYMOUTH MEETING, Pennsylvania, March 25 /PRNewswire-FirstCall/ -- Galil Medical, a global cryotherapy company, today announced that Martin J. Emerson has been appointed President and Chief Executive Officer. Galil Medical is a market leader in cryotherapy technology for the minimally invasive treatment of cancerous and non-cancerous tumours. Mr. Emerson is an experienced and successful medical device industry executive, and was most recently President and CEO of American Medical Systems (AMS). He will be replacing Chen Barir, who will continue to serve on the Galil Medical Board of Directors.

Chen Barir commented, "Galil Medical is very pleased to have been able to attract an executive with the leadership experience and stature of Marty Emerson. We are confident that Marty will be able to help Galil Medical sustain the growth that has been recorded since our December 2006 reorganisation and recapitalisation financing."

"I am very excited to be joining Galil Medical," said Mr. Emerson. "The company has developed innovative cryotherapy solutions to treat prostate cancer and renal tumours and has a promising product pipeline for the Women's Health and Interventional Radiology markets. I look forward to working with the talented team to expand the opportunities for Galil Medical's industry leading technology around the globe."

Mr. Emerson has a strong track record of over 20 years of accomplishments in the medical device industry, most recently as President and Chief Executive Officer of AMS. During his tenure at AMS, he held executive roles including Vice President and General Manager of International, Executive Vice President of Global Sales and Marketing and Chief Operating Officer. Prior to joining AMS, he held senior roles in the overseas operations for several American-based companies including Baxter International and Boston Scientific.

About Galil Medical

Galil Medical develops, manufactures and markets innovative products utilising a proprietary cryotherapy platform that incorporates powerful freezing technology and revolutionary 17-gauge cryoablation needle design. Galil Medical systems enable minimally invasive, targeted ablation of benign and cancerous tumours while ensuring rapid recovery and enhanced quality of life for patients. The Presice(TM) Cryoablation System features multi-point thermal sensors (MTS) and advanced IceVue(TM) planning software for excellent procedure control in treating prostate and renal cancer. The SeedNet(TM) system provides physicians with an easy-to-use cryoablation solution to precisely ablate tumours while protecting adjacent structures.

Galil Medical is a global medical device company with offices in Yokneam, Israel; Plymouth Meeting, Pennsylvania; and London, shareholders include Thomas, McNerney & Partners, The Vertical Group, Investor Growth Capital, Elron Electronic Industries Ltd. (NASDAQ: ELRN) and RDC Rafael Development Corporation, Ltd. For more information, please visit

Pam Schwartz

Communications Manager

Galil Medical

T: +972-4-909-3273

M: +972-52-625-4443

F: +972-4-959-1077

SOURCE Galil Medical
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical to present at BioCentury Conference
2. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
3. Medical Research Award Goes to Adult Stem Cell Scientists at a Kansas Not-for-Profit Organization
4. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
5. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
6. BioMS Medical Announces 2007 Year End Results
7. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
8. GHI Medical Deploys New Test to Help Determine Hair Loss
9. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
10. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
11. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
Breaking Biology News(10 mins):